A947 

A947 is a potent and selective SMARCA2 proteolysis-targeting chimera molecule (PROTAC). A947 also is a potent and moderately selective SMARCA2 degrader. A947 has binding affinity to the SMARCA2 bromodomain with a K_d value of 93 nM. A947 can be used for the research of cancer^[1].

Kd: 93 nM (SMARCA2), 65 nM (SMARCA4); DC50 for SMARCA2: 39 pM (in SW1573 cells)^[1].

A947 has binding affinity to the SMARCA2 and SMARCA4 bromodomains with K_d values of 93 nM and 65 nM, respectively^[1].
A947 can potently degrade SMARCA2 in SW1573 cells with a DC₅₀ value of 39 pM^[1].
A947 (100 nM, 500 nM) mediates ubiquitination and degradation of SMARCA2/4^[1].
A947 (0-500 nM) can inhibit growth of SMARCA4-mutant NSCLC cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

A947 (i.v.; 40 mg/kg; single-dose, 2 week or every other week, 30 days) has active in SMARCA4-mutant NSCLC xenograft models in vivo^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1121.40

C₆₁H₇₆N₁₂O₇S

2378056-80-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jennifer Cantley, et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 2022 Nov 10;13(1):6814.  [Content Brief]